Cellect Biotechnology Ltd., of Tel Aviv, Israel, reported results from a study of 20 patients testing Aprograft on stem cells derived from fat tissue. Apograft increased the number and activity of the fat-derived stem cells from samples obtained through liposuction. Cellect plans to test the process in additional clinical programs and establish licensing deals for the technology.